Rapport Therapeutics (RAPP) awards CDO 120,000 stock options vesting over 4 years

Rhea-AI Filing Summary

Rapport Therapeutics reported that Chief Development Officer Yeleswaram Krishnaswamy received a stock option award. The option gives the right to buy 120,000 shares of common stock at an exercise price of $27.75 per share and expires on February 2, 2036.

The option was granted on February 2, 2026 and vests in 48 equal monthly installments following January 1, 2026, as long as Krishnaswamy continues in service on each vesting date. After this grant, he beneficially owns options for 120,000 shares, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeleswaram Krishnaswamy

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.75	02/02/2026		A		120,000		(1)	02/02/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rapport Therapeutics (RAPP) disclose in this Form 4 filing?

Rapport Therapeutics disclosed a stock option grant to Chief Development Officer Yeleswaram Krishnaswamy. He received options for 120,000 common shares at a $27.75 exercise price, expiring February 2, 2036, vesting monthly over four years starting after January 1, 2026.

How many stock options did Yeleswaram Krishnaswamy receive from Rapport Therapeutics (RAPP)?

He received stock options covering 120,000 shares of Rapport Therapeutics common stock. These options vest in forty-eight equal monthly installments following January 1, 2026, contingent on his continued service with the company on each monthly vesting date.

What is the exercise price and term of the RAPP stock options granted in this filing?

The stock options have an exercise price of $27.75 per share and expire on February 2, 2036. This gives the holder a long-term right to purchase Rapport Therapeutics shares at that fixed price once the options vest.

What is the vesting schedule for Yeleswaram Krishnaswamy’s Rapport Therapeutics options?

The options vest and become exercisable in forty-eight equal monthly installments following January 1, 2026. Vesting is conditioned on Krishnaswamy’s continued service with Rapport Therapeutics on each monthly vesting date throughout the four-year period.

Does this Form 4 show open-market buying or selling of RAPP shares?

No, the Form 4 reports a stock option grant coded as an acquisition of derivative securities. It reflects compensation in the form of options rather than open-market purchases or sales of Rapport Therapeutics common stock by the executive.

How many Rapport Therapeutics options does Krishnaswamy own after this transaction?

After this transaction, Krishnaswamy beneficially owns options for 120,000 shares of Rapport Therapeutics common stock. The filing indicates these derivative securities are held directly, subject to the stated vesting schedule and expiration date.